Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Several other brokerages also recently commented on RTTR. Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital lowered their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.83.

Ritter Pharmaceuticals (NASDAQ RTTR) opened at 0.5022 on Friday. The firm’s market capitalization is $7.41 million. Ritter Pharmaceuticals has a 1-year low of $0.48 and a 1-year high of $3.75. The stock’s 50 day moving average is $0.55 and its 200 day moving average is $0.55.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Analysts predict that Ritter Pharmaceuticals will post ($0.42) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/ritter-pharmaceuticals-inc-rttr-rating-lowered-to-hold-at-zacks-investment-research/1585926.html.

An institutional investor recently raised its position in Ritter Pharmaceuticals stock. KCG Holdings Inc. raised its stake in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the quarter. KCG Holdings Inc. owned 0.91% of Ritter Pharmaceuticals worth $150,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 7.55% of the company’s stock.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.